Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization1 1This manuscript consists of original material not previously accepted for publication by another journal. The manuscript does not include use of any investigational or “off-label” products. The authors do not have a financial or other relationship with any of the commercial enterprises whose products or services may be discussed in this original article.

作者: Lauren Hammock , Melinda Lewis , Carol Phillips , Cynthia Cohen

DOI: 10.1053/S0046-8177(03)00409-X

关键词:

摘要: Breast cancer patients with HER-2/neu oncogene amplification by fluorescence in situ hybridization (FISH) have been shown to a better response trastuzumab (Herceptin) therapy than those showing protein overexpression only. Many centers currently perform FISH only on tumors 2+ positivity immunohistochemistry (IHC), the assumption that 3+ virtually equates amplification. Results of performed 102 breast cases over 12-month period were correlated IHC results. was using ratio and chromosome 17 centromere signal counts (PathVysion; Vysis, Downers Grove, IL). Immunohistochemical expression evaluated according published scoring guidelines HercepTest (Dako, Carpinteria, CA). Only 22 45 (49%) showed FISH. 2 25 staining (6%) gene amplification, 1 negative (4%) weak Of (88%) positivity, (8%) IHC. More 50% strong do not show Most also fail amplify. In our experience, studies should be all avoid inappropriate toxic treatment. The decision IHC-negative guided additional parameters, including tumor grade estrogen receptor status.

参考文章(23)
J A Fletcher, J S Ross, HER-2/neu (c-erb-B2) gene and protein in breast cancer. American Journal of Clinical Pathology. ,vol. 112, ,(1999)
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, T.M. Grogan, Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Journal of Clinical Oncology. ,vol. 19, pp. 2714- 2721 ,(2001) , 10.1200/JCO.2001.19.10.2714
Steven Gutman, Regulatory issues in tumor marker development Seminars in Oncology. ,vol. 29, pp. 294- 300 ,(2002) , 10.1053/SONC.2002.33140
Edith A. Perez, Patrick C. Roche, Robert B. Jenkins, Carol A. Reynolds, Kevin C. Halling, James N. Ingle, Lester E. Wold, HER2 Testing in Patients With Breast Cancer: Poor Correlation Between Weak Positivity by Immunohistochemistry and Gene Amplification by Fluorescence In Situ Hybridization Mayo Clinic Proceedings. ,vol. 77, pp. 148- 154 ,(2002) , 10.4065/77.2.148
C Wright, S Nicholson, B Angus, JRC Sainsbury, J Farndon, J Cairns, AL Harris, CHW Horne, Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. British Journal of Cancer. ,vol. 65, pp. 118- 121 ,(1992) , 10.1038/BJC.1992.22
Nicholas C. Popescu, C.Richter King, Matthias H. Kraus, Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32 Genomics. ,vol. 4, pp. 362- 366 ,(1989) , 10.1016/0888-7543(89)90343-1
Jérôme Couturier, Anne Vincent-Salomon, André Nicolas, Philippe Beuzeboc, Emmanuelle Mouret, Brigitte Zafrani, Xavier Sastre-Garau, Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/ neu ) Gene Status in Breast Carcinoma Modern Pathology. ,vol. 13, pp. 1238- 1243 ,(2000) , 10.1038/MODPATHOL.3880228
Ren L Ridolfi, Mehdi R Jamehdor, Janet M Arber, HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Modern Pathology. ,vol. 13, pp. 866- 873 ,(2000) , 10.1038/MODPATHOL.3880154
Cornelia I. Bargmann, Mien-Chie Hung, Robert A. Weinberg, The neu oncogene encodes an epidermal growth factor receptor-related protein Nature. ,vol. 319, pp. 226- 230 ,(1986) , 10.1038/319226A0